| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(a year from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 24 days from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6537983 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US6759398 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US6878698 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(a year from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 2 months from now) | |
|
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 6 months from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
Trelegy Ellipta is owned by Glaxosmithkline.
Trelegy Ellipta contains Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate.
Trelegy Ellipta has a total of 27 drug patents out of which 7 drug patents have expired.
Expired drug patents of Trelegy Ellipta are:
- US6537983
- US7629335
- US6759398
- US6878698
- US7776895
- US7101866
- USRE44874
Trelegy Ellipta was authorised for market use on 18 September, 2017.
Trelegy Ellipta is available in powder;inhalation dosage forms.
Trelegy Ellipta can be used as maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol, the treatment of an inflammatory disorder of the respiratory tract by once-per-day administration of a pharmaceutical formulation comprising fluticasone furoate and a long-acting beta2 adrenoreceptor agonist, method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application, use of fluticasone furoate for the treatment of an inflammatory or allergic conditions, including chronic obstructive pulmonary disease and asthma, indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; and asthma, the treatment of chronic obstructive pulmonary disease by once-per-day administration of a pharmaceutical formulation comprising fluticasone furoate and a long-acting beta2 adrenoreceptor, method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd, maintenance treatment of asthma in patients 18 yrs and older, or chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema.
Drug patent challenges can be filed against Trelegy Ellipta from 18 December, 2017.
The generics of Trelegy Ellipta are possible to be released after 11 April, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: The treatment of an inflammatory disorder of the respiratory tract by once-per-day administration of a pharmaceutical formulation comprising fluticasone furoate and a long-acting beta2 adrenoreceptor ...
Dosage: POWDER;INHALATION
TRELEGY ELLIPTA family patents
